Investor mix
16 investors on record; lead investors include New Enterprise Associates, Kleiner Perkins; 5 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 7 | 44% |
| Private equity | 5 | 31% |
| Bank & private debt | 1 | 6% |
| Other / undisclosed | 3 | 19% |
Global biopharma innovating medicines in respiratory, immunology, oncology, HIV, and infectious diseases
16 investors on record; lead investors include New Enterprise Associates, Kleiner Perkins; 5 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 7 | 44% |
| Private equity | 5 | 31% |
| Bank & private debt | 1 | 6% |
| Other / undisclosed | 3 | 19% |